Nasoferm

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nasoferm

Property Description
Active Ingredient Xylometazoline hydrochloride
Form Nasal spray, Solution, Nose drops
Pharmacological Class Alpha-adrenergic agonist, Sympathomimetic agent
General Purpose Symptomatic relief of nasal congestion
Origin Synthetic (Imidazole derivative)

Defining Nasoferm: Its Identity and Pharmacological Class

Nasoferm is a trade name for a medication whose active component is Xylometazoline hydrochloride, a compound of the synthetic imidazole derivative class. It is classified as an alpha-adrenergic agonist and a sympathomimetic agent, indicating its mechanism involves targeting the nervous system receptors within the nasal lining. Xylometazoline is recognized as an essential medicine and a local vasoconstrictor. The product is frequently positioned as an Over-The-Counter (OTC) option for rapid, localized relief.


Composition, Presentation, and General Action

The product is formulated as a single-ingredient, clear aqueous solution for direct application. Nasoferm is available as a nasal spray or nose drops, facilitating its delivery via the topical intranasal route. This mode of administration is clinically recognized for maximizing local impact while limiting systemic exposure, which is a key differentiating factor compared to oral decongestants. The primary mechanism of action is vasoconstriction, where Xylometazoline causes the blood vessels lining the nasal passages to narrow. This physiological response reduces the swelling, or edema, of the nasal tissues, which effectively alleviates the primary symptom of nasal congestion.

Regulatory References

  1. WHO Essential Medicines List for Xylometazoline

What side effects are possible with Nasoferm?

Possible Side Effects and Safety Information

The safety profile for Nasoferm (fluticasone propionate nasal spray) is officially documented by government regulatory bodies based on frequency, the body systems affected, and the potential for serious reactions or specific safety constraints.


Frequency-Classified Adverse Reactions

Adverse reactions are classified by how often they may occur:

Classification Examples of Adverse Reactions
Very Common (ge 1/10) Epistaxis (nosebleed)
Common (ge 1/100 to < 1/10) Headache, nasal dryness, throat irritation
Rare to Very Rare (le 1/1,000) Anaphylactic reactions, Glaucoma, Cataract

Serious and Systemic Risks

Although Nasoferm primarily acts locally, rare but serious adverse reactions and systemic effects have been documented:

  • Serious Reactions: Rare events include anaphylactic reactions and angioedema. These are classified under Immune System Disorders.
  • Systemic Effects: The potential for systemic effects, such as adrenal suppression or Cushing's syndrome, exists, particularly with high doses used for prolonged periods or when used concomitantly with strong CYP3A4 inhibitors (e.g., Ritonavir).
  • Ocular Effects: Glaucoma and cataract are listed as very rare effects identified from prolonged treatment and are classified under Eye Disorders.

Population-Specific Safety Constraints

  • Children: The official documents note a risk of growth retardation and advise that the height of children receiving prolonged treatment should be regularly monitored.
  • Drug Interactions: Concomitant use with strong CYP3A4 inhibitors is strongly restricted to avoid increasing the risk of systemic adverse reactions.

Overdose and Emergency Response

Overdose and When to Seek Help

Nasoferm is a proprietary name, and while specific regulatory documents for it are not public, overdose information is based on the authoritative safety warnings for related over-the-counter nasal decongestant sprays. Using higher than recommended doses of these products can lead to serious mental health and cardiovascular problems, which may result in overdose and death.

Overdose Scope

Classification Official Regulatory Information
Documented Presentations Symptoms associated with overdose risk may include severe anxiety or agitation, confusion, paranoia, psychosis, rapid or irregular heartbeat, chest pain or tightness, high blood pressure, and hallucinations.
Dose-Related Factors Overdose risk is associated with using higher than recommended doses or deliberate misuse/abuse.
Emergency Action Seek medical attention immediately by calling emergency services (e.g., 911) or a Poison Control Center right away. Inform healthcare professionals of the product use.

Summary of Risk

The most commonly reported effects in cases of misuse or abuse involve the central nervous and cardiovascular systems, including tremor, delusions, and gastrointestinal symptoms like nausea and vomiting. The primary instruction is to only use the product strictly according to the directions on the label. Accidental or intentional misuse is linked to severe, life-threatening outcomes requiring intensive care.

Therapeutic Uses of Nasoferm

What Nasoferm Treats: Main Uses and Benefits


The primary therapeutic domain of Nasoferm is the management of symptoms related to heightened physiological activity, which is relevant in contexts involving symptoms that create noticeable physiological strain associated with temporary physiological imbalance in the nasal passages. This medication is commonly used across conditions involving episodic or fluctuating manifestations, such as those presenting with systemic or localized discomfort, or those involving inflammatory or irritative processes. This medication is considered relevant in contexts involving symptoms related to physical discomfort.

Managing Episodic Symptomatic Discomfort

Nasoferm is applied in clinical settings that involve acute or unstable symptom patterns to provide supportive relief when symptoms intensify and temporary assistance is needed. It helps address symptom clusters that may become intense or disruptive in conditions presenting with acute episodes. This provides support that contributes to easing the overall symptom load during periods of heightened symptoms.

Stabilizing Disruptive Symptom Manifestations

It is relevant for managing symptom clusters that interfere with daily functioning, where short-term symptomatic assistance is needed. Nasoferm is used to help address symptoms related to physical discomfort, which supports the patient during difficult episodes by easing distress.

Quick Fact: Relevant for Symptoms that Interfere with Daily Functioning

Regulatory References

  1. FASS Patient information on Nasoferm

Eligibility and Restrictions for Use

Contraindicated Populations (Must Not Use)

Nasoferm (Xylometazoline) is contraindicated and must not be used by specific populations as defined in regulatory labeling. These include patients with narrow-angle glaucoma, rhinitis sicca, or known hypersensitivity to the active ingredient or excipients. Use is also strictly prohibited following any recent surgery exposing the dura mater, such as trans-sphenoidal hypophysectomy. Individuals who are currently taking or have taken Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days are also contraindicated from using the medicine.

Conditional and Age-Related Eligibility

Age-Related Eligibility: The 0.1% strength is typically reserved for adults and adolescents aged 12 years and older. Use in children under 6 years is strictly contraindicated. The lower 0.05% strength may be permitted for children aged 6 to 11 years.

Conditional Use: Special caution is advised for patients with certain pre-existing conditions, including hypertension, cardiovascular disorders, hyperthyroidism, diabetes mellitus, and Long QT Syndrome. During pregnancy and lactation, use is generally not recommended as a precaution and should only be undertaken on medical advice.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details the officially documented interaction patterns for Nasoferm (Xylometazoline hydrochloride) as described in regulatory documents.


Regulatory Interaction Classifications

The primary concern in the regulatory interaction profile is pharmacodynamic potentiation—the intensification of Xylometazoline’s intended effects by co-administered substances, leading to cardiovascular risks.

Classification Interacting Substance Class Formal Interaction Restriction
Contraindicated Combination Monoamine Oxidase Inhibitors (MAOIs) Prohibited during treatment and for 14 days after discontinuation of MAOIs.
Use with Caution Tricyclic and Tetracyclic Antidepressants Co-administration requires caution due to the risk of intensifying the drug’s systemic effects.

Official Interaction Statements

Co-administration with MAOIs is formally documented as a contraindicated combination because Xylometazoline can intensify the effect of MAO inhibitors and potentially cause a hypertensive crisis. This risk establishes a mandatory two-week (14-day) administration-timing restriction following the cessation of MAOI therapy.

Use with caution is specified for tricyclic and tetracyclic antidepressants. These agents may potentiate the sympathomimetic and systemic effects of Xylometazoline, which can result in a documented increase in blood pressure.

No formal interaction patterns are officially documented in regulatory sources for food, alcohol, herbal products, CYP enzymes, or major drug transporters.

Mechanism of Action

Nasoferm contains xylometazoline, an imidazoline derivative that functions as a direct-acting alpha-adrenergic receptor agonist. Its pharmacodynamic action is selectively localized to the nasal mucosa.

The molecule primarily interacts with and activates alpha1- and alpha2-adrenoceptors expressed on the vascular smooth muscle cells lining the small arteries and arterioles of the nasal turbinates and venous sinusoids. The activation of alpha1-adrenoceptors initiates a Gq protein-coupled signaling cascade, which involves the activation of phospholipase C and subsequent mobilization of intracellular calcium ions (Ca^2+). This intracellular Ca^2+ increase is the molecular trigger for smooth muscle cell contraction.

Simultaneously, the activation of alpha2-adrenoceptors, which are Gi protein-coupled, leads to the inhibition of adenylyl cyclase. This reduces the synthesis of the second messenger cyclic adenosine monophosphate (cAMP), further contributing to the contractile state of the vascular muscle.

These combined molecular and cellular pathways result in vasoconstriction of the localized submucosal vasculature. The systemic physiological consequence is a reduction in blood flow to the venous sinusoids and a resultant decrease in the volume of the blood-filled vascular spaces within the nasal lining, thus modulating airflow resistance.

Dosage and Administration Information

How to Use Nasoferm

Administration of Xylometazoline (Nasoferm) is based on specific, regulatory-defined parameters detailing the route, concentration, frequency, and duration of use. The medicine is delivered via the topical intranasal route, which is essential for proper function.

Official Dosing and Frequency

Age Group Concentration Dosing Regimen Frequency Limit
Adults & Adolescents (ge 12 yrs) 1 mg/mL (0.1%) 2 to 3 sprays or drops per nostril Maximum of 3 applications per 24 hours
Children (2 to 11 yrs) 0.5 mg/mL (0.05%) 1 to 2 sprays or drops per nostril Maximum of 3 applications per 24 hours

The 1 mg/mL strength is not approved for use in children under 10 or 12 years, depending on the specific national label, and the medication is generally not recommended for children under two years of age.

Use Protocol and Constraints

The usage schedule mandates a specific time interval between applications, requiring that doses be spaced no more often than every 8 to 10 hours. Before application, patients should ensure their nose is gently blown. Furthermore, metered-dose spray devices must be primed before the initial use to ensure the delivery of the correct quantity. A crucial regulatory constraint dictates that the medication must be used only for a short-term course, typically not longer than 5 to 7 consecutive days. This duration limit governs the full use protocol as established in official prescribing information.

Recent Clinical Evidence

Research evidence / Overview of studies for Nasoferm

Evidence for Symptomatic Relief of Nasal Congestion

Research for Xylometazoline hydrochloride was studied for outcomes related to physical discomfort, exploring how symptoms change over time, particularly in conditions characterized by fluctuating or episodic manifestations such as the common cold, allergic rhinitis, and sinusitis. This research primarily consists of short-term Randomized Controlled Trials (RCTs) and Systematic Reviews that synthesize the findings from various trials.

These studies were evaluated in populations of adults and adolescents experiencing episodes where symptoms become more noticeable. Research examined outcomes related to physical discomfort, focusing on patient-reported outcomes describing perceived discomfort and severity scores related to congestion. Trials also monitored objective changes measured during the study period in the nasal passages, such as nasal airflow and objective assessments of swelling.

Evidence in Different Population Groups

Research was evaluated in specific age-defined groups. The main body of evidence applies to Adults and Adolescents (typically ge 12 years). Research was studied for Younger Children (typically 2–10 years) using formulations with lower amounts of the active ingredient. Studies help show what has been observed so far regarding symptom patterns in different developmental stages.

However, data for certain groups remain insufficient. Dedicated clinical studies focusing specifically on the older adult population are limited in number. This means that evidence patterns for symptom changes in this particular subgroup are not fully established, and results apply only to the populations studied in the primary clinical trials.

Areas of Uncertainty and Research Gaps

Clinical research highlights several areas where data are still emerging or where the evidence is limited. The follow-up durations were limited to short periods in the core efficacy studies, meaning there is limited information for long-term outcomes regarding the medication's effects. Furthermore, detailed information on the drug’s profile, including its systemic absorption, metabolism, and elimination in humans, data for certain groups remain insufficient.

Key Studies & References

  1. The efficacy of xylometazoline, the risk of rhinitis medicamentosa (RM), and treatment strategies: A review of published studies (Review/Meta-analysis)
  2. SUMMARY OF PRODUCT CHARACTERISTICS: Xylometazoline hydrochloride 0.05% w/v nasal spray solution (Regulatory Monograph)
  3. Xylometazoline - WHO Electronic Essential Medicines List (EML Status)

Frequently Asked Questions (FAQ)

Common questions about Nasoferm (FAQ)


Q: Can Nasoferm be used for non-allergic congestion?

A: Yes, official product information indicates that Nasoferm is used for the symptomatic relief of nasal congestion. This general purpose applies to congestion caused by various factors, including the common cold, allergic rhinitis, and other non-allergic causes.


Q: What is the difference between Nasoferm and a standard saline spray?

A: Nasoferm contains Xylometazoline, an active medicine classified as an alpha-adrenergic agonist that causes vasoconstriction (narrowing of blood vessels) to actively reduce nasal swelling. Standard saline sprays are non-medicinal products that contain no active drug and work by moisturizing or washing the nasal passages.


Q: Can I use Nasoferm just when my symptoms are bad?

A: Official instructions mandate that Nasoferm must only be used for a short-term course, typically not longer than 5 to 7 consecutive days. Regulatory constraints specify this short duration is a precaution against the risk of rebound congestion (rhinitis medicamentosa), which is the return or worsening of symptoms.


Q: Does Nasoferm have any impact on the sense of smell?

A: While the regulatory documents do not commonly list a total loss of smell, the documented side effects include nasal dryness and irritation. These local effects may temporarily affect the nasal environment and the perception of smell.


Q: Are there any long-term risks associated with using Nasoferm regularly?

A: Regulatory documents warn that using Nasoferm for a period longer than the recommended short-term course (5 to 7 days) is associated with the risk of developing rebound congestion (rhinitis medicamentosa), which causes symptoms to worsen. Use should not exceed the specified duration.


Q: Can Nasoferm be used to treat a common cold?

A: Nasoferm is officially indicated for the symptomatic relief of nasal congestion. This means it helps clear a stuffy nose associated with conditions like the common cold, but it is not a medicine designed to treat the underlying viral cold itself.


Q: Is Nasoferm safe for adults over 65?

A: Official labeling advises that special caution is necessary for patients with pre-existing conditions common in older adults, such as hypertension (high blood pressure) and cardiovascular disorders. The labeling advises special caution for use in these patient groups due to the potential for systemic absorption of the drug.


Q: Can Nasoferm be used by people with glaucoma?

A: Nasoferm is strictly contraindicated (must not be used) in people who have been diagnosed with narrow-angle glaucoma. Individuals with any history of glaucoma should discuss the use of Nasoferm with their healthcare provider.


Q: Does Nasoferm cause nasal dryness or nosebleeds?

A: Yes, regulatory documents list both of these as potential adverse reactions. Nasal dryness is a common side effect, and epistaxis (nosebleeds) is listed as a very common adverse reaction associated with Nasoferm use.


Q: Why do doctors often prescribe Nasoferm for chronic sinus issues?

A: Nasoferm is indicated for the symptomatic relief of congestion associated with conditions like sinusitis. However, due to the regulatory constraint limiting use to a short-term course, the medication is generally positioned for acute relief of temporary congestion and not for long-term chronic management.


Q: Can Nasoferm be used by people with a history of heart problems?

A: The regulatory label advises special caution for patients with cardiovascular disorders and hypertension. This is because Xylometazoline, as a sympathomimetic agent, has the potential for systemic absorption that requires medical oversight in individuals with heart conditions.


Q: What does Nasoferm feel like when you first use it?

A: Regulatory safety information indicates that common local side effects that may be felt when first using the spray include a burning, stinging, or sensation of dryness inside the nose. These local effects are generally temporary.


Q: Are there any foods or supplements that interact with Nasoferm?

A: Official regulatory sections regarding drug interactions state that no formal interaction patterns are officially documented for food, alcohol, or herbal products when using Nasoferm. The primary regulatory concern relates to interactions with specific prescription medications.


Q: What are the signs of an allergic reaction to Nasoferm?

A: Rare, serious signs of an allergic reaction listed in regulatory safety information include anaphylactic reactions and angioedema, which involves swelling of the face, tongue, lips, or throat. These are considered severe events that require immediate medical attention.


Q: What is the shelf life of an unopened bottle of Nasoferm?

A: When stored correctly, official product information often grants a shelf life for the unopened bottle of up to 60 months (5 years) from the date of manufacture. Always check the expiration date printed on the packaging.


Q: What are the inactive ingredients found in Nasoferm?

A: The official product labeling lists the inactive ingredients (excipients). These commonly include a preservative, such as benzalkonium chloride, along with water and various buffering agents used to stabilize the solution.


Q: Does Nasoferm cause any changes in appetite?

A: Regulatory documents detailing common and rare side effects do not list changes in appetite as a known adverse effect associated with the use of Nasoferm.


Q: Can Nasoferm affect my sleep?

A: Side effects that may impact sleep, such as restlessness and other sleep disturbances, have been reported as very rare events in the product’s safety documentation.


Q: Does Nasoferm contain gluten or lactose?

A: Nasoferm is a liquid nasal solution, and its inactive ingredients generally do not contain excipients like lactose or gluten, which are commonly found in oral tablets. The full list of excipients is available in the official product labeling.


Q: What clinical trials have been done on Nasoferm?

A: Regulatory approvals are based on data derived primarily from short-term Randomized Controlled Trials (RCTs). These studies evaluated the drug's efficacy and safety in populations experiencing nasal congestion associated with conditions like the common cold and allergic rhinitis.


Q: Is Nasoferm a maintenance or an acute-relief medication?

A: Based on regulatory use constraints that mandate a short duration of use, typically no longer than 5 to 7 consecutive days, Nasoferm is officially categorized as an acute-relief medication, not a long-term maintenance treatment.


Q: Is Nasoferm safe during pregnancy?

A: Due to limited data on its use in humans and the potential for systemic effects, use during pregnancy is generally not recommended as a precautionary measure. Any use during pregnancy requires consultation with a healthcare professional.

How should Nasoferm be stored and disposed of?

How to Store and Dispose of Nasoferm

Nasoferm (Xylometazoline) must be stored strictly according to official regulatory requirements to maintain its stability.

Storage and Handling Requirements:

Condition Requirement
Temperature Store below 30 C (or 77 F).
Environment Protect from direct heat, sunlight, and moisture.
Packaging Keep the container tightly closed and use only in the original container.
Safety Keep the medicine out of the sight and reach of children.

Disposal Requirements:

Unused or expired Nasoferm should not be disposed of in household trash or wastewater. Official guidelines recommend using a drug take-back program or following local pharmaceutical waste regulations. If a take-back program is unavailable, mix the medicine with an undesirable substance (such as used coffee grounds) in a sealed bag before discarding to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nasoferm found in:

A-Z Index: